BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products.
Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success.
Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers.
BDD aims to be the most respected science-based and IP focussed integrated pharmaceutical development centre trusted with the sectors most demanding drug delivery challenges.
For more than 20 years, BDD has provided expertise in early phase clinical research for the pharmaceutical industry using gamma scintigraphic imaging techniques. Gamma scintigraphic studies enable the visualisation of formulation behaviour in man and are a powerful tool in product development. Through conducting these evaluative clinical studies, BDD Scientists have gained a unique understanding of how pharmaceutical products work in vivo.
In 2010, we founded sister company Drug Delivery International (DDI) Ltd, to develop our patented controlled release technology OralogiK™ and offer formulation development services to our clients. In 2017, DDi and Bio-images Research came together as BDD Pharma Ltd to offer our clients combined formulation development and clinical services.
Our experience of biopharmaceutics is what drives our science and sets us apart from our competitors. We understand the complexities of drug development and have created an integrated clinical and manufacturing service enabling rapid in vivo evaluation of novel products saving our clients considerable time and expense during product development.
BDD continue to invest in future technologies and research (particularly in the modified release field) to ensure we offer our clients solutions to their challenges as well as providing the patients of tomorrow with enhanced treatments to improve quality of life.
Carol was co-founder and COO of Drug Delivery International Ltd for three years prior to becoming CEO of BDD Pharma. With more than 20 years’ experience of management in the sciences sector, Carol has developed strong operational management and leadership skills and has led the growth of BDD as an integrated development and clinical trials company, including two successful funding rounds. Carol has a degree in Genetics from the University of Glasgow and a PhD from the University of Sheffield.
Laura has been with BDD for over 12 years and has more than 15 years experience in the pharmaceutical sector. She has extensive expertise in GMP manufacturing and clinical trial management. Laura is responsible for business operations across the clinical and development divisions of BDD, leading our expert teams to deliver on BDD’s vision and strategy. Laura has an MChem from Heriot Watt University.
Catherine is a member of the Chartered Institute of Management Accountants and brings a wealth of experience having managed company finances, teams and projects over the last 35 years. She has experience in the Professional, Public and Private Sector allowing best practice to be used to drive performance at all levels within the business. She supports ongoing financial reporting, business planning and budgeting ensuring compliance with HMRC and Financial Regulations.
Fiona is Director of Biopharmaceutics at BDD. A registered pharmacist, she has more than 20 years’ experience in formulation development, with a focus on controlled release and chronotherapeutics. Fiona has extensive expertise in vivo evaluation of novel formulations. Through her work in this area, she has gained an in depth understanding of how different formulations will perform in man which she uses to guide intelligent formulation design. Fiona has a PhD and degree in Pharmacy from the University of Strathclyde.
Calum Stevens is Commercial Director and has been with BDD Pharma for more than 12 years. Responsibilities include strategizing and implementing sales and marketing campaigns, managing the company branding and facilitating client acquisition. Calum has previous experience with successfully running & founding his own company, Lomond Marine. Externally Calum sits on the board at Carers Link as a Non-Executive Director and as Chairman of Communications Subgroup. He is also a member of the Management Committee of the Loch Lomond Rescue Boat. Calum studied Marine Biology at the University of Aberdeen.
Our success is built upon solid scientific ability, strengthened by shared values across the company. Our commitment to our clients is at the forefront of everything we do.
Joanne Kelley has a long and extensive experience of global commercial and general management in the pharmaceutical industry and has led a range of transactions including M&A, technology licensing and collaboration arrangements. Previously in her role as Vice President of Business Development, Head of Transactions at AstraZeneca, Jo was responsible for a number of transformational deals and has received a number of awards recognising her deal making achievements. As well as her position as Chair of BDD, Jo is a non- executive Director for The University of Manchester Innovation Factory, a Director of Alderley Park Ventures and a Business Development consultant for UK lifescience companies.
Dr Carol Thomson has had a varied career in management in the science sector and developed strong operational management and leadership skills at Thomson Reuters, where she managed the Pharmaceutical Patents Business Unit of the World Patents Index. Following this, Carol spent three years at the University of Strathclyde in a Research Business Development role and subsequently as Research Policy Manager. Carol has a degree in Genetics and PhD from the University of Sheffield.
Professor Howard Stevens is a registered pharmacist whose career spans four decades of management of industrial research and development in the UK and Europe in large multinationals and small drug delivery companies. He has been involved in the formation of several successful spin-out businesses and served as the Pfizer Professor of Drug Delivery at the University of Strathclyde from 1998-2009. He has an extensive scientific and patent publication record, is a fellow of the RPSGB, RSC and APSGB and served as Chairman of the APSGB in 2001.
Glenn Crocker is an experienced CEO, company founder, non-executive director and investor in the life sciences sector.
He was founding CEO of BioCity Group from mid-2003, becoming Executive Chairman at the start of 2019. In April 2021 BioCity was acquired by Trinity Investment Management and a new company, We Are Pioneer Group Ltd (WAPG) was created, of which Glenn is a director. He has a DPhil in Immunology from Oxford University and qualified as a chartered accountant with EY, working with biotech companies in Palo Alto, California and Cambridge, UK, where he headed up the UK Biotech practice for EY.
Glenn runs the Ventures arm of BioCity Group (now WAPG) and has co-founded, invested in and exited many successful life science companies.
He is a non-executive director of BioAscent Discovery, Alderley Park Ventures and the UK Science Parks Association and a governor of Trent College.
In 2014 Glenn received an MBE for services to the biotechnology industry.
Stephen is a PhD Pharmacist (Queens University, Belfast) with 30+ years experience in Pharmaceutical product development. During his career he has worked with a number of large Pharma and Biotech companies including Sterling Winthrop, Sanofi, Chiroscience, Celltech, and UCB. He has experience with a wide range of dosage forms, (oral and injectable), drug delivery technologies and devices and established and led Pharmaceutical Development teams responsible for the successful development of a number of new chemical entities (NCEs) and antibody products with total peak annual sales in excess of $3Bn, including Oxaliplatin and Cimzia.
Claire has more than 20 years experience in the pharmaceutical sector, Claire was an Executive Director at Molecular Profiles Ltd and served as Senior Vice President at Juniper Pharma Services Ltd at the time of its sale to Catalent for $140m in 2018.
As a senior executive, Claire has proven success in delivering growth, building from a small spin out to an organisation with over 200 employees. She currently acts as an independent consultant to the investment community and to pharmaceutical companies, providing support on growth, investment strategies and due diligence.
World Class Drug Delivery Company
Glasgow Royal Infirmary
84 Castle St
Glasgow
G4 0SF, UK
+44 (0)141 552 8791
Bio-City Scotland
Bo’ness Road
Chapelhall, Newhouse
ML1 5UH, UK
+44 (0)141 404 9540
